Inflammation plays a n important role in atherosclerosis and plaque vulnerability (1) . Activated macrophages contribute to both atherosclerotic plaque disruption and intracoronary thrombus formation, often leading to acute coronary syndromes (ACS). Plaque disruption usually takes place at the thinnest fibrous cap and is mostly infiltrated with macrophages (2) . The activated macrophages p roduce inflammatory cytokines, protease, and cytotoxic oxygen and nitrogen radical molecules (3) . Macrophages activated by interferon-(IFN-) also synthesize neopterin (4) .
Neopterin, a pteridine derivative and a byproduct o f the guanosine triphosphate-biopterin pathway and p roduced b y activated m onocyte (5, 6 ) is thought to represent a marker of immune activation and macrophage activity (4) . It is elevated in a number of autoimmune and infectious disease states (6) . Because of its relative stability and ease of assay has made it a subject for research as a mean to m onitor disease activity. Acute inflammatory markers such as high neutrophil count, hs-CRP, and neopterin concentration correlate with the presence of multiple angiographically complex coronary stenoses. Neopterin concentration was considered as a stronger predictor of m ultiple complex plaques than were neutrophil count and hs-CRP (7) .
A previous study has shown that serum neopterin is an independent predictor of major adverse coronary Introduction events in those with chronic stable angina pectoris (8) . It is also elevated in patients with ACS compared to those with stable ischemic heart disease (9). Likewise, high serum neopterin levels predict the development of acute coronary events in women with chronic stable angina pectoris (10) and hypertensive patients without significant obstructive coronary artery disease (CAD) (11) . Until recently, unfortunately, there has been lack of scientific information on the prognostic value of neopterin in ACS in non-Caucasian population. Only one study reported elevated plasma neopterin level, which might identify patients at long-term risk of death or recurrent acute coronary events after ACS in Caucasian (12) .
In the present study we prospectively measured the associations between elevated serum neopterin and increased risk of cardiovascular (CV) events in ACS in Bali. Specifically, we assessed the relative risk of elevated serum neopterin in association with CV events and survival rate of patients with ACS.
P atients & Methods

PATIENTS AND STUDY PROTOCOLS
This was a prospective cohort study carried out from January 31 to August 31, 2007, involving 77 ACS patients admitted to Sanglah Hospital of Udayana University School o f Medicine, Denpasar -Bali. Patients with ACS (aged 30 -74 years) were consecutively recruited in the study, who had agreed to participate by signing the written informed consent. The local ethics committee of our hospital approved the study. This is a top referral Public Hospital (teaching hospital as well) for Bali Island and its surrounding smaller islands.
Exclusion criteria included ACS s ubjects with rheumatic heart disease, acute and c hronic liver disease, chronic kidney disease ( represented b y creatinin clearance using Cockroft Gault formula ≤ 60 ml/1.73 m2/min), infectious disease, and malignancy. DEFINITIONS OF CARDIOVASCULAR RISK FACTORS Hypertension w as diagnosed i n the p resence of a systolic blood pressure of ≥ 140 mmHg and/or diastolic blood pressure of ≥ 90 mmHg as measured on at least two separate occasions. Patients receiving antihypertensive m edications w ere also r egarded to s uffer hypertension, irrespective o f the blood pressure recordings at study entry (13) . Patients were considered to have diabetes m ellitus if they w ere taking active treatment with insulin or oral hypoglycemic agents, or the fasting blood glucose ≥ 126 mg/dL and/or random blood glucose ≥ 200 m g/dL (14) . Hypercholesterolemia was defined as a documented total cholesterol concentration > 200 mg/dL. Smoking status was defined as: a) non-smoker for those who never had smoked, b) ex-smoker, for those who ever had smoked but already had quit at study entry, c) current smoker, those which was active smoker at study entry (15) . Obesity was diagnosed by measuring body mass index.
BIOCHEMICAL MEASUREMENTS
Venous blood was collected from all subjects at the time of admission for routine laboratory examination. Serum neopterin concentration was taken a t 3rd hospitalization d ay, and m easured using a commercially available immunoassay kit (ELISA Kit, IBL, Hamburg, Germany) b y a qualified laboratory technician blinded to clinical characteristics and CV events. The within-coefficient variability was 3.6 -6.8% in the 7.7 -48 nmol/L range; it has very good correlation with HPLC (high performance liquid c hromatography) measurement (r = 0.97). Limit of detection reached as low as 0.7 nmol/L (16). Neopterin concentrations were divided into quartile ranges with regard to planned analysis, as shown by previous study (12) .
CLINICAL CHARACTERIZATION, FOLLOW-UP, AND CLINICAL OUTCOMES Data acquired at study entry included age, gender, height, weight, blood pressure, risk factors history including diabetes m ellitus, hypertension, and family history of CAD, smoking, dyslipidemia. Killip classification and the Canadian Cardiovascular Society (CCS) functional class, as well as cardiac medications were recorded at study entry.
After recruitment, r outine baseline characterization was carried out in all subjects, who were then followed for up to 7 months of study period. All subjects, after discharged from the hospital were encouraged to visit the outpatient clinic unit of Sanglah Hospital. Subjects who did not regularly visit the hospital were further followed up by performing home visit. This effort was made to avoid loss-to follow-up. At the end of study, a total of 71 ACS subjects remained in the analysis, and 6 subjects had refused to participate.
The c ardiovascular events determined as p respecified clinical outcomes for this analysis included CV mortality, recurrent myocardial infarction, stroke and r ecurrent m yocardial ischemia. These clinical outcomes were assessed by research assistants.
STATISTICAL ANALYSIS Prior to beginning of the study, we calculated the number of the patients needed to have a power of 80% with predicted relative risk of 3.7 at the 0.05 level of significance. The estimated minimal sample size was 70.
Normally distributed continuous variables were expressed as the mean ± standard deviation (SD), and continuous variables w ith non-normal distribution were presented as median values (interquartile range). Analysis o f normality o f the continuous variables PARTICIPANTS Initially 77 subjects with ACS were recruited in the study, o f which approximately 40% had a n index diagnosis of ST-elevation myocardial infarction (MI), 13% had a diagnosis o f non-ST elevation M I and the rest had unstable angina. Eventually, 71 subjects remained in the analysis and 6 subjects refused to participate without any reason. No loss to follow-up was noted in this study.
Neopterin concentrations were divided into quartile ranges. Elevated serum neopterin g roup was those subjects with neopterin concentration ≥ 14.72 nmol/L. Along 213 median-days of follow-up, 21 (28.2%) subjects underwent CV events. Baseline clinical characteristics, biochemical and t reatment pattern results are shown in Table 1 . All the clinical characteristics, biochemical and treatment pattern are identical between groups.
CLINICAL OUTCOMES
The c ardiovascular events determined as p respecified clinical outcomes for this analysis included CV m ortality, r ecurrent M I, stroke and r ecurrent myocardial ischemia, a s presented in Table 2 . Along 213 median-days of follow-up, 28.2% subjects underwent CV events, namely: 4 (19.0%) subjects had CV deaths, 2 (9.5%) had recurrent MI and 15 (71.5%) subjects suffered recurrent myocardial ischemia.
KAPLAN-MEIER SURVIVA L CURVE
Kaplan-Meier survival curve shows that the highest quartile g roup o f neopterin had survival curve significantly worse than those in the lowest quartile group (log-rank test; P = 0.047), as presented in Figure  1 . The highest quartile group had the mean survival shorter compared to the lowest quartile group {69.7 (95% CI: 48.1 -91.2 days) vs. 190.5 (95% CI: 161.1 -219.8); P = 0.047 days}.
RISK OF CARDIOVA SCULAR EVENTS After multivariable adjustment, the relative risk of CV events is significantly associated with a serum neopterin concentration o f ≥ 14.72 nmol/L (RR, 5.84 [95% CI: 1.19 to 28.47]; P = 0.029). Before being adjusted with other predictors, the RR was 6.63 (95% CI: 1.37 to 32); P = 0.018. The other predictors being considered as important risk factors were age, history of hypertension, diabetes mellitus, and family history of CAD.
Results was performed with the Kolmogorov-Smirnov test.
Homogeneity of variance was also tested using the Leven's test.
In order to have true association between elevated serum neopterin and clinical outcomes of interest, we constructed a Cox proportional model that adjusted for age, history of diabetes mellitus, hypertension, and family history o f CAD t o assess r elative risk over 7 months. Relative risk was expressed with 95% confidence interval. Survival rate was also determined using Kaplan-Meier survival curve. Differences were considered to be statistically significant if the null hypothesis would be rejected with > 95% confidence. The SPSS 13.0 statistical software package was used for calculations.
The authors had full access to the data and take full responsibility for its integrity. All authors have read and agree to the manuscript as written. The r esults of our study show that neopterin, a biomarker of activated macrophage, predicts adverse CV events during follow-up in subjects with ACS. To our knowledge, this is the first clinical study performed in non-Caucasian population. After m ultivariable adjustment, patients in the highest quartile of serum neopterin concentrations had a 5 to 6-fold higher risk of developing adverse CV events than those in the lowest quartile. This association was present across a range of baseline characteristics and was statistically significant after adjustment for conventional risk factors, biochemical and treatment allocation. Thus, serum neopterin may be useful as prognostic factor in patients with ACS. Our results confirm and are consistent with previous findings from other study (12) . This finding strongly suggests that increased activation o f monocyte-macrophage system i s a specific feature of high-risk ACS patient for CV death or recurrent acute coronary events. Increased c irculating T -lymphocyte activity, which leads to elevated production of interferon-, is implicated in the pathogenesis of ACS (17) . CD4 + and CD8 + T-lymphocyte are proven to activate in patients with unstable angina and their activation state lasts 6 to 8 weeks (18) . They are largely of the T-helper (Th1) subtype, which secretes interleukin-2, tumor necrosis factor-and interferon-, which causes macrophage activation, vascular activation, and inflammation (19) . Production o f neopterin b y activated m acrophage is mainly in response to stimulation by interferonreleased b y activated T-lymphocyte (19) . Consequently, serum neopterin concentrations m ay r epresent the whole state of cell-mediated immunity within subjects with ACS.
Serum neopterin as a biomarker of macrophage activation is significantly increased in patients with AMI and unstable angina shortly after the onset of symptoms (after period of 72 hours) (20) . Further, in regard to reliability of neopterin measurement, there is no significant 'sex dependence' and values for subjects younger or older than 75 years w ere significantly higher (21). This i s the r eason why w e measured neopterin at 3 rd hospitalization day, and the age-range of our sample was only limited from 30 to 74 years old. The present study may be considered to be valid based on several reasons: a) the recruited samples represent the population of ACS in Bali, with spectrum Discussion ranged from unstable angina, NSTEMI and STEMI (22) , b) the follow-up was long enough for assessing the clinical outcomes, with 213 median-days, c) the clinical outcomes were assessed with no knowledge of the result of studied variable (neopterin), d) there were adjustments performed in order to prove the true association between neopterin concentration and the risk of CV events.
Recently, the prognostic value of elevated serum neopterin was studied in chronic stable angina pectoris (8) . The cut-off point of neopterin to predict future adverse cardiac events in that study is lower than ours (7 nmol/L vs. 14.72 nmol/L). This lower cut-off point is basically due to different studied population, namely chronic stable angina which represents less inflammatoric state than ACS population. Large-scale data on neopterin cut-off points in ACS actually are lacking. Ray et.al. (2007) determined neopterin cutoff point of ≥ 12.11 nmol/L in ACS population (12) . Although the population is about the same as ours, but the cut-off point i s even lower. P robably, our population is more inflammatoric, as represented by higher proportion of CV risk factors found (such as, diabetes mellitus, hypertension and LDL-cholesterol concentration). Percentage of STEMI in our study is more than Ray's study. Another reported study on 210 patients with NSTEMI from the FLORIDA (Fluvastatin On Risk Diminishing after Acute myocardial infarction) trial used a threshold of 9.7 nmol/L, which represented the lower limit of the upper tertile. But it showed similar results to the present finding over a 1-year period of follow-up (23) .
LIMITATION OF THE STUDY
The study limitation i s the r elatively s mall size of r ecruited subjects, though the study power is statistically modest. The neopterin cut-off point of ≥ 14.72 nmol/L used to define a higher level in the present study was not specified a priori and was based on the available neopterin data post hoc. Nevertheless, validation of this cut-off point in ACS population needs to be clarified in large prospective study. However, even with the relatively small sample size, elevated serum neopterin concentration was considered as a useful prognostic factor. CONCLUSION Our study shows that elevated s erum neopterin concentrations are associated with development of adverse CV events in ACS patients. This association is independent of the severity of ACS and baseline CV risk factors, as well as treatment allocation.
